je.st
news
Ichor Partner Scancell Announces Update on SCIB1 Phase 1/2 Clinical...
2015-06-02 21:34:40| Logistics - Topix.net
Ichor Medical Systems, Inc. is pleased to announce that their partner Scancell Holdings plc presented updated and very encouraging data from the ongoing Phase 1/2 clinical trial of SCIB1, its DNAi 1 2ImmunoBody being developed for the treatment of patients with melanoma, at the American Society of Clinical Oncology meeting in Chicago. The trial is ani 1 2open label, non-randomized study to characterize the safety and tolerability of SCIB1 administeredi 1 2using Ichor's TriGridTM delivery system, as well as provide initial assessment of the ability of SCIB1 to delay ori 1 2prevent disease recurrence in patients with Stage III/IV melanoma.
Tags: partner
update
phase
clinical
Category:Transportation and Logistics